BRPI0821115A8 - Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto - Google Patents

Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto

Info

Publication number
BRPI0821115A8
BRPI0821115A8 BRPI0821115A BRPI0821115A BRPI0821115A8 BR PI0821115 A8 BRPI0821115 A8 BR PI0821115A8 BR PI0821115 A BRPI0821115 A BR PI0821115A BR PI0821115 A BRPI0821115 A BR PI0821115A BR PI0821115 A8 BRPI0821115 A8 BR PI0821115A8
Authority
BR
Brazil
Prior art keywords
compound
drug
pharmaceutical composition
aminotriazole
aminotriazole derivative
Prior art date
Application number
BRPI0821115A
Other languages
English (en)
Inventor
Grisostomi Corinna
Cren Sylvaine
Leroy Xavier
Bur Daniel
Corminboeuf Olivier
Richard-Bildstein Sylvia
Original Assignee
Actelion Pharmaceuticals Ltd
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BRPI0821115A2 publication Critical patent/BRPI0821115A2/pt
Publication of BRPI0821115A8 publication Critical patent/BRPI0821115A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTO DERIVADO DE AMINOTRIAZOL, MEDICAMENTO, COMPOSIÇÃO FARMACÊUTICA E USO DO COMPOSTO. Refere-se a presente invenção aos derivados de aminotriazol da fórmula (I), em que A, E, R1 e R2 são tais como definidos na descrição, sua preparação e seu uso como compostos farmaceuticamente ativos. Os compostos são de utilidade para a prevenção ou tratamento de enfermidades, as quais reagem à modulação do receptor de ALX, tais como enfermidades inflamatórias.
BRPI0821115A 2007-12-18 2008-12-17 Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto BRPI0821115A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2007055199 2007-12-18
IB2008054369 2008-10-23
PCT/IB2008/055375 WO2009077990A1 (en) 2007-12-18 2008-12-17 Aminotriazole derivatives as alx agonists

Publications (2)

Publication Number Publication Date
BRPI0821115A2 BRPI0821115A2 (pt) 2015-06-16
BRPI0821115A8 true BRPI0821115A8 (pt) 2017-12-26

Family

ID=40404773

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821115A BRPI0821115A8 (pt) 2007-12-18 2008-12-17 Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto

Country Status (26)

Country Link
US (1) US8536209B2 (pt)
EP (1) EP2225231B1 (pt)
JP (1) JP4656674B2 (pt)
KR (1) KR101213007B1 (pt)
CN (1) CN101903378B (pt)
AR (1) AR069801A1 (pt)
AT (1) ATE520689T1 (pt)
AU (1) AU2008337097B2 (pt)
BR (1) BRPI0821115A8 (pt)
CA (1) CA2706839C (pt)
CY (1) CY1112465T1 (pt)
DK (1) DK2225231T3 (pt)
HK (1) HK1144158A1 (pt)
HR (1) HRP20110825T1 (pt)
IL (1) IL206399A (pt)
MA (1) MA31949B1 (pt)
MX (1) MX2010006241A (pt)
MY (1) MY153985A (pt)
NZ (1) NZ586735A (pt)
PL (1) PL2225231T3 (pt)
PT (1) PT2225231E (pt)
RU (1) RU2492167C2 (pt)
SI (1) SI2225231T1 (pt)
TW (1) TWI434685B (pt)
WO (1) WO2009077990A1 (pt)
ZA (1) ZA201005080B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
AR078508A1 (es) 2009-05-18 2011-11-16 Actelion Pharmaceuticals Ltd Derivados spiro [2.4]heptano puenteados, composiciones farmaceuticas y uso de los mismos
JP5095035B2 (ja) * 2009-06-09 2012-12-12 アクテリオン ファーマシューティカルズ リミテッド フッ素化アミノトリアゾール誘導体
CA2760887A1 (en) * 2009-06-12 2010-12-16 Actelion Pharmaceuticals Ltd Oxazole and thiazole derivatives as alx receptor agonists
CN103221392B (zh) 2010-11-17 2015-06-03 埃科特莱茵药品有限公司 桥联螺[2.4]庚酯衍生物
KR101864463B1 (ko) 2010-12-07 2018-06-04 이도르시아 파마슈티컬스 리미티드 Alx 수용체 작용제로서의 옥사졸릴-메틸에테르 유도체
AR084172A1 (es) * 2010-12-07 2013-04-24 Actelion Pharmaceuticals Ltd Derivados aminotriazol hidroxilados como agonistas del receptor alx
WO2012152741A1 (de) 2011-05-10 2012-11-15 Bayer Intellectual Property Gmbh Bicyclische (thio)carbonylamidine
EP2739143B1 (en) * 2011-08-05 2018-07-11 Gary A. Flynn Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
CN102558117B (zh) * 2011-12-15 2014-10-08 北京金骄生物质化工有限公司 一种利用废弃生物质制备5-硝基-2-糠酸酯的方法
CN104284887B (zh) 2012-05-16 2016-06-22 埃科特莱茵药品有限公司 作为alx受体激动剂的经1-(对-甲苯基)环丙基取代的桥联螺[2.4]庚烷衍生物
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
CA2873341C (en) 2012-06-04 2018-01-02 Actelion Pharmaceuticals Ltd Benzimidazole-proline derivatives
BR112015007516A2 (pt) 2012-10-10 2017-07-04 Actelion Pharmaceuticals Ltd antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona
CN104968657A (zh) * 2012-12-03 2015-10-07 弗·哈夫曼-拉罗切有限公司 被取代的三唑和咪唑化合物
KR20150130413A (ko) 2013-03-12 2015-11-23 액테리온 파마슈티칼 리미티드 오렉신 수용체 길항제로서의 아제티딘 아미드 유도체
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
US9533964B2 (en) 2013-07-18 2017-01-03 Actelion Pharmaceuticals Ltd. Piperazine substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
SG11201604296QA (en) 2013-11-28 2016-07-28 Kyorin Seiyaku Kk Urea derivative or pharmacologically acceptable salt thereof
HUE040555T2 (hu) 2013-12-04 2019-03-28 Idorsia Pharmaceuticals Ltd Benzimidazol prolin származékok alkalmazása
US10858314B2 (en) 2015-05-27 2020-12-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
CN107849049B (zh) 2015-05-27 2021-03-16 杏林制药株式会社 脲衍生物或其药用盐
EP3380091A1 (en) * 2015-11-24 2018-10-03 Bristol-Myers Squibb Company Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease
BR112020017744A2 (pt) 2018-03-05 2020-12-22 Bristol-Myers Squibb Company Agonistas do receptor do peptídeo fenilpirrolidinona formila 2
US11629143B2 (en) 2020-10-01 2023-04-18 Vibliome Therapeutics, Llc HipK4 inhibitors and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62234018A (ja) 1986-04-02 1987-10-14 Rooto Seiyaku Kk 糖尿病併発症治療剤
AU2002359311A1 (en) 2001-10-26 2003-05-06 Government Of The United States Of America, As Represented By The Secretary, Department Of Health An Amyloid ss is a ligand for fpr class receptors
EP1492552A2 (en) 2002-04-03 2005-01-05 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
CA2544983A1 (en) * 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
CN1997633A (zh) * 2004-05-25 2007-07-11 麦它波莱克斯股份有限公司 作为ppar调节剂的取代的三唑及其制备方法
EP1828148B1 (en) * 2004-12-13 2010-01-20 Leo Pharma A/S Triazole substituted aminobenzophenone compounds
CA2626897A1 (en) * 2005-11-03 2007-05-18 Joshua Close Histone deacetylase inhibitors with aryl-pyrazolyl motifs
CA2651072A1 (en) * 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
CN104130247B (zh) 2007-08-21 2018-06-01 塞诺米克斯公司 人t2r苦味受体及其用途
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
AR078508A1 (es) 2009-05-18 2011-11-16 Actelion Pharmaceuticals Ltd Derivados spiro [2.4]heptano puenteados, composiciones farmaceuticas y uso de los mismos
JP5095035B2 (ja) 2009-06-09 2012-12-12 アクテリオン ファーマシューティカルズ リミテッド フッ素化アミノトリアゾール誘導体
CA2760887A1 (en) 2009-06-12 2010-12-16 Actelion Pharmaceuticals Ltd Oxazole and thiazole derivatives as alx receptor agonists

Also Published As

Publication number Publication date
RU2010129272A (ru) 2012-01-27
KR101213007B1 (ko) 2012-12-20
MY153985A (en) 2015-04-30
JP4656674B2 (ja) 2011-03-23
WO2009077990A1 (en) 2009-06-25
CN101903378B (zh) 2014-03-12
BRPI0821115A2 (pt) 2015-06-16
MX2010006241A (es) 2010-06-30
HRP20110825T1 (hr) 2011-12-31
AR069801A1 (es) 2010-02-17
KR20100092516A (ko) 2010-08-20
CA2706839A1 (en) 2009-06-25
HK1144158A1 (en) 2011-01-28
IL206399A (en) 2016-03-31
PL2225231T3 (pl) 2012-01-31
MA31949B1 (fr) 2010-12-01
RU2492167C2 (ru) 2013-09-10
US20100331378A1 (en) 2010-12-30
AU2008337097B2 (en) 2014-03-20
TW200932216A (en) 2009-08-01
IL206399A0 (en) 2010-12-30
ZA201005080B (en) 2011-12-28
CA2706839C (en) 2015-10-20
CN101903378A (zh) 2010-12-01
TWI434685B (zh) 2014-04-21
US8536209B2 (en) 2013-09-17
EP2225231A1 (en) 2010-09-08
JP2011506594A (ja) 2011-03-03
DK2225231T3 (da) 2011-10-17
EP2225231B1 (en) 2011-08-17
SI2225231T1 (sl) 2011-12-30
PT2225231E (pt) 2011-10-19
ATE520689T1 (de) 2011-09-15
AU2008337097A1 (en) 2009-06-25
NZ586735A (en) 2012-06-29
CY1112465T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
BRPI0821115A8 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0720220B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo
BRPI0821004A8 (pt) Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
UY30759A1 (es) Compuestos quimicos
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
BRPI0915064B8 (pt) derivados de quinoxalinadiona, seus usos, e medicamentos
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
BRPI1011657A2 (pt) derivados aminopropiônicos substituídos como inibidores de neprilisina
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
BRPI0717156B8 (pt) inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende
DOP2010000259A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
BRPI0716171A8 (pt) Composto, composição farmacêutica e uso de um composto
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
BRPI0918750B8 (pt) derivado de 2-carboxamida cicloamino ureia, seu uso e sua composição farmacêutica
BR112013001088A2 (pt) "derivados substituídos como inibidores a quinase de imidazoquinolina"
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
BR112012011793A2 (pt) "acrilamidas heterocíclicas e seu uso como farmacêuticos"
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
BR112013000254A2 (pt) derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
BRPI0714553B8 (pt) derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso
BRPI0713443A2 (pt) Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B25C Requirement related to requested transfer of rights

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2545 DE 15-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.